TRDA Profile
Entrada Therapeutics, Inc. is a pioneering biotechnology company specializing in the development of endosomal escape vehicle (EEV) therapeutics designed to treat a range of neuromuscular diseases. The company is at the forefront of innovation with its EEV platform, which enables the delivery of therapeutic agentsâ€including oligonucleotides, antibodies, and enzymesâ€into the cells by overcoming the barriers posed by endosomal entrapment. This platform holds the potential to revolutionize treatment approaches for several challenging and rare conditions.
The company’s lead product candidate, ENTR-601-44, is advancing through preclinical trials with the aim of treating Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). DMD is a severe, progressive muscle disorder, while DM1 is a genetic condition characterized by muscle weakness and other systemic effects. ENTR-601-44 leverages Entrada's EEV technology to enhance the delivery and efficacy of therapeutic agents specifically targeting the underlying causes of these diseases.
In addition to ENTR-601-44, Entrada Therapeutics is developing EEV-PMO-CAG, a therapeutic candidate focused on addressing myotonic dystrophy type 1. This program utilizes the company’s proprietary EEV platform to deliver a peptide nucleic acid that targets the CAG repeat expansion in the DM1 gene. By specifically targeting the genetic mutation responsible for DM1, EEV-PMO-CAG aims to provide a more effective and targeted treatment for patients suffering from this condition.
Founded in 2016 and headquartered in Boston, Massachusetts, Entrada Therapeutics was formerly known as CycloPorters, Inc., before rebranding in October 2017. The company continues to advance its innovative EEV technology with the goal of addressing significant unmet medical needs in neuromuscular diseases. Through its cutting-edge approach to drug delivery and its focus on rare, debilitating conditions, Entrada Therapeutics is poised to make substantial contributions to the field of biotechnology and improve outcomes for patients worldwide.
|
